The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...

A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound. Starting in mid-November, customers with a prescription ...

Viking Therapeutics is developing a weight loss medicine ... approved by the Food and Drug Administration is Eli Lilly's tirzepatide, a therapy that is smashing pharmaceutical industry sales records, ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political ...

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.